BioCryst Pharmaceuticals, Inc.  

(Public, NASDAQ:BCRX)   Watch this stock  
Find more results for BCRX
8.34
0.00 (0.00%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.17 - 8.69
52 week 1.42 - 13.33
Open 8.28
Vol / Avg. 364,954.00/899,130.00
Mkt cap 499.98M
P/E     -
Div/yield     -
EPS -0.55
Shares 59.95M
Beta 3.11
Inst. own 67%
May 8, 2014
Q1 2014 BioCryst Pharmaceuticals Earnings Release (Tentative) Add to calendar
May 2, 2014
BioCryst Pharmaceuticals Annual Shareholder Meeting - 3:00PM EDT - Add to calendar
Apr 9, 2014
BioCryst Pharmaceuticals at Needham Life Sciences Conference
Mar 12, 2014
BioCryst Pharmaceuticals at Barclays Healthcare Conference
Mar 10, 2014
BioCryst Pharmaceuticals at ROTH Conference
Mar 3, 2014
BioCryst Pharmaceuticals at Cowen Health Care Conference
Feb 26, 2014
Q4 2013 BioCryst Pharmaceuticals Earnings Conference Call
Feb 26, 2014
Q4 2013 BioCryst Pharmaceuticals Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -51.38% -173.72%
Operating margin -59.94% -177.24%
EBITD margin - -175.48%
Return on average assets -42.67% -56.64%
Return on average equity -1906.80% -
Employees 40 -
CDP Score - -

Address

2190 PARKWAY LAKE DR
BIRMINGHAM, AL 35244
United States - Map
+1-205-4444600 (Phone)
+1-919-8591314 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. BioCryst designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on therapeutic areas. Peramivir is its product, which is a neuraminidase inhibitor for the treatment of patients with influenza. The Company has two purine nucleoside phosphorylase (PNP) inhibitors that are in development, BCX4208 for the treatment of gout and forodesine for the treatment of hematological malignancies. The Company's pre-clinical compounds include BCX4161, an oral prophylactic drug for hereditary angioedema, and BCX5191, an adenine nucleoside analog targeting viral ribonucleic acid (RNA) polymerase for the treatment of hepatitis C.

Officers and directors

Jon P. Stonehouse President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Thomas R. Staab II Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
Age: 48
Bio & Compensation  - Reuters
William P. Sheridan Senior Vice President, Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Yarlagadda S. Babu Ph.D. Vice President - Drug Discovery
Age: 60
Bio & Compensation  - Reuters
George B. Abercrombie Non-Executive Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Fred E. Cohen M.D., Ph.D. Director
Age: 56
Bio & Compensation  - Reuters
Stanley C. Erck Independent Director
Age: 64
Bio & Compensation  - Reuters
Nancy J. Hutson Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters